Literature DB >> 15576511

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Christophe Lo Bianco1, Bernard L Schneider, Matthias Bauer, Ali Sajadi, Alexis Brice, Takeshi Iwatsubo, Patrick Aebischer.   

Abstract

Parkinson's disease (PD) is characterized by a progressive loss of midbrain dopamine neurons and the presence of cytoplasmic inclusions called Lewy bodies. Mutations in several genes including alpha-synuclein and parkin have been linked to familial PD. The loss of parkin's E3-ligase activity leads to dopaminergic neuronal degeneration in early-onset autosomal recessive juvenile parkinsonism, suggesting a key role of parkin for dopamine neuron survival. To evaluate the potential neuroprotective role of parkin in the pathogenesis of PD, we tested whether overexpression of wild-type rat parkin could protect against the toxicity of mutated human A30P alpha-synuclein in a rat lentiviral model of PD. Animals overexpressing parkin showed significant reductions in alpha-synuclein-induced neuropathology, including preservation of tyrosine hydroxylase-positive cell bodies in the substantia nigra and sparing of tyrosine hydroxylase-positive nerve terminals in the striatum. The parkin-mediated neuroprotection was associated with an increase in hyperphosphorylated alpha-synuclein inclusions, suggesting a key role for parkin in the genesis of Lewy bodies. These results indicate that parkin gene therapy may represent a promising candidate treatment for PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576511      PMCID: PMC536019          DOI: 10.1073/pnas.0405313101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?

Authors:  M S Goldberg; P T Lansbury
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

2.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

3.  CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.

Authors:  Leonard Petrucelli; Dennis Dickson; Kathryn Kehoe; Julie Taylor; Heather Snyder; Andrew Grover; Michael De Lucia; Eileen McGowan; Jada Lewis; Guy Prihar; Jungsu Kim; Wolfgang H Dillmann; Susan E Browne; Alexis Hall; Richard Voellmy; Yoshio Tsuboi; Ted M Dawson; Benjamin Wolozin; John Hardy; Mike Hutton
Journal:  Hum Mol Genet       Date:  2004-02-12       Impact factor: 6.150

4.  Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease.

Authors:  N Déglon; J L Tseng; J C Bensadoun; A D Zurn; Y Arsenijevic; L Pereira de Almeida; R Zufferey; D Trono; P Aebischer
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

5.  Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.

Authors:  C J Cummings; E Reinstein; Y Sun; B Antalffy; Y Jiang; A Ciechanover; H T Orr; A L Beaudet; H Y Zoghbi
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

6.  Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.

Authors:  Takeshi Iwatsubo
Journal:  J Neurol       Date:  2003-10       Impact factor: 4.849

7.  Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients.

Authors:  H Shimura; N Hattori; S Kubo; M Yoshikawa; T Kitada; H Matsumine; S Asakawa; S Minoshima; Y Yamamura; N Shimizu; Y Mizuno
Journal:  Ann Neurol       Date:  1999-05       Impact factor: 10.422

Review 8.  Silver staining as a tool for neurotoxic assessment.

Authors:  C A Beltramino; J S de Olmos; F Gallyas; L Heimer; L Záborszky
Journal:  NIDA Res Monogr       Date:  1993

9.  CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.

Authors:  Hideki Shimura; Daniel Schwartz; Steven P Gygi; Kenneth S Kosik
Journal:  J Biol Chem       Date:  2003-11-10       Impact factor: 5.157

10.  Hereditary early-onset Parkinson's disease caused by mutations in PINK1.

Authors:  Enza Maria Valente; Patrick M Abou-Sleiman; Viviana Caputo; Miratul M K Muqit; Kirsten Harvey; Suzana Gispert; Zeeshan Ali; Domenico Del Turco; Anna Rita Bentivoglio; Daniel G Healy; Alberto Albanese; Robert Nussbaum; Rafael González-Maldonado; Thomas Deller; Sergio Salvi; Pietro Cortelli; William P Gilks; David S Latchman; Robert J Harvey; Bruno Dallapiccola; Georg Auburger; Nicholas W Wood
Journal:  Science       Date:  2004-04-15       Impact factor: 47.728

View more
  105 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 2.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 3.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 4.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 5.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

Review 6.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

7.  Viral vectors as a tool to model and treat Parkinson's disease.

Authors:  Jean-Charles Bensadoun; Patrick Aebischer
Journal:  Wien Klin Wochenschr       Date:  2006-10       Impact factor: 1.704

8.  Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  J Mol Biol       Date:  2006-12-21       Impact factor: 5.469

9.  Optimization of Tet1 ligand density in HPMA-co-oligolysine copolymers for targeted neuronal gene delivery.

Authors:  David S H Chu; Joan G Schellinger; Michael J Bocek; Russell N Johnson; Suzie H Pun
Journal:  Biomaterials       Date:  2013-09-13       Impact factor: 12.479

10.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.